Real-world long-term outcomes of non-small cell lung cancer patients undergoing neoadjuvant treatment with or without immune checkpoint inhibitors.

Chin Med J (Engl) · 2025 · PMC12634232 · PMID 40108795

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a significant trendno p-value reported

We also found that patients with stage I–II disease who received NAIT had a more favorable prognosis than those who received NACT [Supplementary Figures 2A, B, http://links.lww.com/CM9/C375 ], whereas a significant trend was not observed in patients with stage III disease [Supplementary Figures 2C, D, http://links.lww.com/CM9/C375 ].

also in 9,775 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.